Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Melanoma 20Neoplasms 13Breast Neoplasms 11Stomach Neoplasms 9Pancreatic Neoplasms 9Neoplasm Metastasis 9Lung Neoplasms 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Prostatic Neoplasms 4Hodgkin Disease 4Glioblastoma 4Carcinoma, Transitional Cell 4Carcinoma 4Uterine Cervical Neoplasms 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Adenocarcinoma 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Squamous Cell 2Mesothelioma 2

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nonsquamous Non-small Cell Lung Cancer × pembrolizumab × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡